

1 **The stromal-vascular fraction of adipose tissue contributes to major differences**
2 **between subcutaneous and visceral fat depots**

3 Juan R. Peinado, Yolanda Jimenez-Gomez, Marina R. Pulido, Maria Ortega-Bellido, Cesar
4 Diaz-López, Francisco J. Padillo, Jose López-Miranda, Rafael Vazquez-Martínez, Maria M.
5 Malagon

6 Department of Cell Biology, Physiology and Immunology, University of Córdoba, (J.R.P., Y.J.-
7 L., M.R.P., M.O.B, R.V.-M., M.M.M.); Instituto Maimónides de Investigación Biomédica
8 (IMIBIC), University of Córdoba (J.R.P., Y.J.-L., M.R.P., M.O.B, J.L.M., R.V.-M., M.M.M.);
9 CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III
10 (J.R.P., Y.J.-L., M.R.P., M.O.B, R.V.-M., M.M.M.); Department of General Surgery (C.D.-L.,
11 F.J.P.) and Lipid and Atherosclerosis Research Unit (J.L.M.), Reina Sofía University Hospital,
12 Córdoba, Spain.

13 **Brief title:** *Proteomic dissection of fat depots (SAT vs. VAT)*

14 **Address for correspondence:** María M. Malagón. Department of Cell Biology, Physiology and
15 Immunology. Campus Universitario de Rabanales. Edificio Severo/ Ochoa, Pl. 3. University of
16 Córdoba. E-14014 Córdoba. Spain. Phone: +34 957 21 22 56. Fax: +34 957 21 86 34. E-mail:
17 bc1mapom@uco.es

18 **Disclosure Summary:** The authors have nothing to disclose

19 **Grant support:** This work was supported by Ministerio de Ciencia e Innovación (MICINN)/FEDER
20 (BFU2007-60180/BFI to MMM, FPU AP2005-3348 to MRP), Junta de Andalucía (CTS-03039, and BIO-
21 0139 to MMM), and CIBER Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Spain.

22 **Keywords:** Adipose tissue, lean, MALDI-TOF mass spectrometry, mature adipocytes,
23 proteome, stromal-vascular fraction, 2D-PAGE.

24

25 We have identified proteins whose expression differs between visceral and
26 subcutaneous adipose tissue and which may be implicated in the pathologies that differentially
27 affect each fat depot.

28

29

30 **Abstract**

31

32 Adipose tissue represents a complex tissue both in terms of its cellular composition, as
33 it includes mature adipocytes (MA) and the various cell types comprising the stromal-
34 vascular fraction (SVF), and in relation to the distinct biochemical, morphological and
35 functional characteristics according to its anatomical location. Herein, we have
36 characterized the proteomic profile of both MA and SVF from human visceral (VAT)
37 and subcutaneous (SAT) fat depots in order to unveil differences in the expression of
38 proteins which may underlie the distinct association of VAT and SAT to several
39 pathologies. Specifically, 24 proteins were observed to be differentially expressed
40 between SAT SVF *vs.* VAT SVF from lean individuals. Immunoblotting and RT-PCR
41 analysis confirmed the differential regulation of the nuclear envelope proteins Lamin
42 A/C, the membrane-cytoskeletal linker ezrin and the enzyme involved in retinoic acid
43 production, ALDH1A2, in the two fat depots. In sum, the observation that proteins with
44 important cell functions are differentially distributed between VAT and SAT and their
45 characterization as components of SVF or mature adipocytes, pave the way for future
46 research on the molecular basis underlying diverse adipose tissue-related pathologies
47 such as metabolic syndrome or lipodystrophy.

48

49

50

51

52

53

54

55

56 **Introduction**

57 Adipose tissue is a highly active metabolic tissue and important endocrine organ which,
58 together with its classical role as energy storage depot, produces a wide variety of molecules
59 with signaling properties (i.e. adipokines) that are involved in multiple functions including the
60 regulation of metabolism, energy homeostasis, as well as immunity and inflammation (reviewed
61 in (1). Far from being a simple organ, adipose tissue exhibits a marked heterogeneity both in
62 terms of its cellular composition and in relation to its anatomical location. Thus, it is composed
63 of mature adipocytes which are immersed in a complex collagen matrix wherein blood cells and
64 preadipocytes coexist with nerve terminals and vascular tissue (2). These latter cellular
65 components, comprising the stromal-vascular fraction (SVF), can be separated from mature
66 adipocytes by enzymatic methods. This approach has enabled to show that adipokines are not
67 only secreted by adipocytes but also by SVF cells (3), yet differences exist in the type and
68 amount of molecules produced by each component. Accordingly, whereas adipokines such as
69 leptin and adiponectin are primarily secreted by adipocytes (3), SVF cells contribute to most of
70 the release of inflammatory mediators and interleukins such as Tumor Necrosis Factor-alpha
71 (TNF- α) or interleukin-6 (IL-6) (4). These and other adipose-derived factors participate in the
72 induction and maintenance of the subacute proinflammatory state associated with obesity that is
73 commonly linked to the development of insulin resistance and type 2 diabetes (5).

74 In addition, the different adipose tissue depots exhibit unique adipokine expression and
75 secretion profiles (for review (1). Importantly, VAT has been associated with increased risk for
76 multiple morbidities including the metabolic syndrome (6) or type 2 diabetes (7). On the other
77 hand, SAT is most highly associated with several cases of lipodystrophy, such as those related
78 with several laminopathies (8).

79 By studying the proteome of mature adipocytes and the SVF of VAT and SAT, we have
80 established the protein fingerprints of the different components of adipose tissue and showed
81 that major differences between VAT and SAT can be attributed to the SVF proteome.
82 Furthermore, in this scenario, we have identified proteins whose expression differs between the

83 two fat depots which may be related to the distinct pathologies associated to VAT or SAT such
84 as metabolic syndrome or lipodystrophy.

85

86 **Subjects and Methods**

87 **Subjects**

88 The study was approved by the Ethical Committee of Reina Sofia Hospital (Córdoba, Spain)
89 and all patients involved gave informed consent. Paired samples (7-8 g) of abdominal adipose
90 tissue obtained from VAT and SAT of 14 Caucasian individuals (10 men and 4 women)
91 undergoing elective open-abdominal surgery were collected between 9:00 and 11:00 AM.
92 Subjects were 50 to 70 yr old with normal weight (Table 1). None of the individuals presented
93 any chronic disease, diabetes, metabolic syndrome or altered biochemical parameters that could
94 indicate adipose tissue alterations. Immediately after removal, biopsies were washed in DMEM
95 (Invitrogen, Barcelona, Spain) and divided into 2-3 pieces, which were either frozen in liquid
96 nitrogen and stored at -80°C or processed for the separation of mature adipocytes and SVF.

97 **Isolation of mature adipocytes and SVF**

98 Freshly isolated SAT and VAT biopsies were collected in Krebs-Ringer Hepes medium (119
99 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO₄, 2.5 mM CaCl₂, 1.2 mM KH₂PO₄, 20 mM Hepes pH
100 7.4, 2 mM glucose, 2% BSA) and washed twice to eliminate peripheral blood. Next, samples
101 were incubated in Krebs-Ringer Hepes medium with 400 a.u./ml of collagenase (type V, Sigma,
102 St Louis, MO) at 37°C for 1 h in a shaking bath. Undigested tissue was removed by filtering
103 through a sterile 100 µm pore Cell Strainer (BD Falcon, CA) and centrifuged at 600g for 10 min
104 to separate the floating mature adipocyte layer from the pelleted SVF. Mature adipocytes were
105 washed with DMEM, frozen in liquid nitrogen and stored at -80°C. SVF was resuspended in
106 DMEM, filtered through a 40 µm pore Cell Strainer and centrifuged at 400g for 5 min. Pelleted
107 SVF was resuspended in 500 µl of erythrocyte lysis buffer (RBC Lysis Solution, Puregene,
108 MN) and incubated for 3 min at RT. After centrifugation at 400 g for 10 min, SVF was frozen in
109 liquid nitrogen and stored at -80°C until protein extraction.

110 **Protein extraction**

111 Total adipose tissue and mature adipocytes were thawed in 0.4 ml of cold Urea/thiourea
112 buffer [7 M urea, 2 M thiourea, 4% CHAPS, 45 mM Tris pH 7.4, 60 mM DTT, and complete
113 protease inhibitors (1 tablet/20 ml, Roche, Barcelona, Spain)] supplemented with 0.1 mM NaCl.
114 Cells were mechanically disrupted and briefly sonicated. Samples were adjusted to 900 µl with
115 lysis buffer (20 mM Tris pH 7.4, 100 mM NaCl, 1% Triton and protease inhibitors) and
116 incubated for 15 min at 35°C. After cooling on ice (10 min), 100 µl of 0.1 M Tris pH 7, and 50
117 mM MgCl₂ were added to the homogenates, which were then incubated with DNase I (30 U,
118 Sigma) on ice (10 min). The homogenate was centrifuged (15 min, 10000g, 4°C) and the
119 aqueous phase between the upper lipid phase and lower cellular debris phase was collected.
120 Extensive delipidation was accomplished by Tri-n-butylphosphate-acetone-methanol
121 precipitation (9). SVF was disrupted in 200 µl of lysis buffer. Extract was incubated with DNase
122 I (30 U, Sigma) for 10 min in ice followed by standard chloroform/methanol precipitation.
123 Precipitated proteins were resuspended in 75 µl of Urea/thiourea buffer. After Bradford assay
124 for protein quantification, samples were diluted to 7 µg/µl with Urea/thiourea buffer and frozen
125 at -20°C.

126 **Isoelectric focusing and 2D-PAGE**

127 350 µg of protein from whole adipose tissue (n=3), mature adipocytes (n=3) and SVF (n=4)
128 obtained from paired samples of SAT and VAT were diluted in 300 µl of Rehydration Buffer
129 and 0.8% of 3-10NL IPG buffer (GE Healthcare, Barcelona, Spain). Immobilized pH gradient
130 strips (18cm, pH 3–10NL) were processed in an Ettan IPGPhor 3 System (GE Healthcare)
131 following manufacturer instructions. Strips were equilibrated in SDS Equilibration Buffer [75
132 mM Tris, pH 8.8, 6 M urea, 30% glycerol, 2% SDS] containing 2% DTT for 15 min, followed
133 by a 15-min wash with equilibration buffer containing 2.5% iodoacetamide. Proteins were
134 separated on 12% Tris-glycine gels using an Ettan Dalt Six device (GE Healthcare), which
135 resolved proteins with a MW higher than 20 kDa. Gels were stained with SYPRO Rubi dye
136 and/or 0.1% Coomassie brilliant blue G-250, 10% ammonium sulfate, 2% phosphoric acid and
137 20% methanol.

138

139 **MALDI-TOF-MS analysis**

140 Spots were excised automatically in a ProPic station (Genomic Solutions, Huntingdon, UK)
141 and subjected to MS analysis. For MALDI-TOF-MS analysis, gel specimens were destained
142 twice (30 min, 37 °C) with 200 mM ammonium bicarbonate/40% acetonitrile. Gel pieces
143 dehydrated for 5 min with pure acetonitrile and dried out over 4 h were automatically digested
144 with trypsin according to standard protocols in a ProGest station (Genomic Solutions). MS and
145 MS/MS analyses of peptides of each sample were analyzed in a 4,700 Proteomics Station
146 (Applied Biosystems, CA).

147 **Immunoblotting**

148 Frozen samples from 4 additional individuals were disrupted in TBS buffer [20 mM Tris pH
149 7.4, 150 mM NaCl, 1% Triton and protease inhibitors] and incubated in the presence of DNase I
150 (30 u; Sigma) on ice (15 min). 30-70 µg of protein were loaded on 10% SDS-PAGE and
151 transferred to nitrocellulose membranes (Biotrace, Pall, Germany). After Ponceau staining to
152 ensure equal sample loading, membranes were blocked for 1 h with 5% dried milk in TBS
153 buffer with 0.05% Tween-20. After overnight incubation at 4°C with the corresponding primary
154 antibody, membranes were incubated with the appropriate IgG-HRP-conjugated secondary
155 antibody. Immunoreactive bands were visualized with an enhanced-chemiluminescence reagent
156 (Chemiluminescent HRP substrate, Millipore, MA). Optical densities of the immunoreactive
157 bands were measured using ImageJ 1.40g software. Data were normalized to the corresponding
158 β-actin band intensities.

159 **Total RNA isolation and Real-Time PCR**

160 Samples of VAT and SAT SVF obtained from at least 4 additional individuals were
161 homogenized with an ULTRA-TURRAX T10 basic (IKA® Werke GmbH, Staufen, Germany)
162 using TRIZOL® Reagent (Invitrogen). Total RNA samples were digested with RQ1 DNase
163 (Promega, Sydney, NSW) before RT-PCR. The expression levels of VAT-1 and ALDH1A2
164 genes, and of 18S ribosomal RNA (rRNA) as housekeeping gene, were measured by RT-PCR
165 using an iCycler™ Real-Time PCR System (Bio-Rad Laboratories, Hercules, CA). Specifically,
166 1 µg of total RNA underwent random primed reverse transcription using a First Strand cDNA

167 Synthesis kit (Fermentas, Burlington, ON, Canada). Real-Time PCR was carried out with 1 μ l
168 of cDNA and 24 μ l of reaction mixture [12.5 μ l of 2 x SYBR Green Supermix (Bio-Rad)], 9.5
169 μ l of RNase-free water and 1 μ l of the corresponding primers [VAT-1: sense,
170 TCCTCTTTGACTTCGGCAAC; antisense, TGTGACCCCATTCCTTCA, ALDH1A2:
171 sense, CAGTGTGGAGAAGGATGGATG; antisense, GCCTGCGTAATATCGAAAGGT, and
172 18S: sense, CCCATTCGAACGTCTGCCCTATC; antisense,
173 TGCTGCCTTCCTTGGATGTGGTA]. After an initial hold of 2 min at 94°C, samples were
174 cycled 40 times at 94 °C for 15 s and at 61 °C for 15 s. For quantitative analysis, standard curve
175 based method for relative Real-Time PCR data processing was utilized. The expression of each
176 target gene was normalized to that of the housekeeping gene. All measurements were performed
177 in duplicate. Controls consisting of reaction mixture without cDNA were negative in all runs.

178 **Data analysis**

179 2-D gel analysis was performed by PDQuest software (Bio-Rad), version 8.0. In order to
180 reduce false positives, only those proteins with consistent differences of more than 1.5 times
181 between samples were included in the analysis. Manual corrections were also performed to
182 validate the matches automatically generated by the software. Spot volume values were
183 normalized in each gel by dividing the raw quantity of each spot by the total volume of all the
184 spots included in the same gel. Other normalizations provided by the PDQuest software were
185 also performed with similar results. Variations of all the identified spots were finally confirmed
186 and quantified by density measurements using ImageJ 1.40g software.

187 Statistical analysis used SSPS statistical software, version 11.0 for WINDOWS (SSPS INC.,
188 Chicago, IL). Normal distribution of variables to characterize differences in the expression of
189 proteins under study was assessed using the Kolmogorov-Smirnov Test followed by a Student's
190 T test for independent samples. Differences were considered significant at $P < 0.05$. All data are
191 expressed as mean \pm S.E.M.

192

193 **Results**

194 **Comparative 2D electrophoresis**

195 Approximately 800 spots were observed in the gels prepared from whole adipose tissue
196 extracts and from the separate fractions (mature adipocytes and SVF) of VAT and SAT (Figs. 1
197 and 2). Irrespective of the fat depot, analysis of the master gel obtained with the integrated
198 proteome of mature adipocytes and SVF revealed that both subsets shared nearly 60% of the
199 total number of spots detected. The remaining 40% of the spots corresponds to proteins
200 exclusively present in the proteome of mature adipocytes (21%) or in that of SVF (19%).

201 Comparative proteomic analysis of mature adipocytes from VAT and SAT of lean
202 individuals revealed the lack of consistent differences between them (Fig. 1B). This pattern was
203 reproducible in the three distinct pairs of samples analyzed. In contrast, analysis of all spots
204 present in the four distinct proteomes from paired visceral and subcutaneous SVF included in
205 this study revealed 24 spots that were significantly different in SAT SVF *vs.* VAT SVF (Fig. 2).
206 Of these, 17 were up-regulated and 7 were down-regulated in SVF from VAT *vs.* SAT (Table
207 2). The identified proteins could be grouped into the following categories: i) molecular
208 chaperones and stress response (HSP70, chaperonin containing TCP1, and hSP56), ii)
209 metabolism (3-phosphoglycerate dehydrogenase), ii) cytoskeleton and cell membrane-related
210 events (cytokeratins KRT7, 8, 18, 19, coronin, ezrin, annexins A5, A7, A9 and A3, lamin A/C),
211 iii) transport (transferrin), iv) adipose-derived hormones (visfatin, omentin), and v) redox state
212 [aldehyde dehydrogenase A1 (ALDH1A1) and A2 (ALDH1A2), vesicle amine transport protein
213 1 (VAT-1)]. Among these proteins, only ezrin, hSP56, ALDH1A1, KRT7, KRT8, KRT18,
214 and KRT19 were also observed to be differentially expressed when the proteomes of whole
215 VAT and SAT were compared (Fig. 1 and Supplemental Table 1). However, differences in the
216 relative abundance of these proteins were more evident in SVF proteomes than in the proteomes
217 of whole tissue extracts, as shown for ANXA5, hSP56 and KRT18 in Fig. 3. On the other hand,
218 when the proteomes of whole VAT and SAT were compared, we could identify several
219 differentially expressed proteins that were not detected in the analysis of the proteomic maps of
220 the separate SVF. These included additional cytoskeletal proteins (*i.e.*, caldesmon 1, β -
221 tropomyosin, and desmin, up-regulated in VAT; gelsolin, up-regulated in SAT), the chaperone

222 HSP27 (up-regulated in VAT) and gamma and beta fibrinogen (Fig. 1 and Supplemental Table
223 1).

224 **Western Blot analysis of Lamin A/C and Ezrin**

225 One protein overexpressed in the SVF of each depot was chosen for confirmation by western
226 blot, one preferentially expressed in SAT, lamin A/C, and one more abundant in VAT, ezrin. As
227 shown in Fig. 4A, two distinct immunoreactive bands were revealed using the anti-lamin A/C
228 antiserum, corresponding to lamin A (74 kDa) and lamin C (65 kDa), in both VAT SVF and
229 SAT SVF. Quantification of the immunoreactive bands confirmed up-regulation of both lamin
230 A (1.34 fold) and lamin C (1.53 fold) in SAT SVF. Conversely, ezrin was up-regulated (3 fold)
231 in VAT SVF (Fig. 4B).

232 **Expression of VAT-1 and ALDH1A2 mRNA**

233 Up-regulation of VAT-1 (2.2 fold) in SAT SVF and of ALDH1A2 (12.0 fold) in VAT SVF
234 were documented with RT-PCR (Fig. 5).

235

236 **Discussion**

237 Over the last years, an increasing number of studies have focused on the analysis of the
238 differences in the transcriptome, proteome and secretome between SAT and VAT [reviewed in
239 (10), (11)], given their distinct characteristics regarding, among others, adipokine production,
240 metabolic activity, proliferative capacity, apoptotic rate or adipocyte size, as well as their
241 differential contribution for the development of various diseases (6, 12, 13). However, most of
242 these studies were performed on whole adipose tissue preparations and only a few number
243 employed human samples (14-16). Herein, we report for the first time the proteomes of isolated
244 adipocytes and SVF from human VAT and SAT.

245 Our results showed that the protein fingerprints of isolated adipocytes from VAT and SAT
246 of lean individuals were strikingly similar whereas significant differences were observed
247 between the SVF of both fat depots in terms of their protein expression patterns. We have to
248 include the caveat that, due to the technical limitations imposed by the high lipid content of
249 adipocytes and/or to possible alterations induced by the cell separation protocol, our analysis

250 has likely skipped low represented or specific proteins that might be differentially expressed by
251 isolated adipocytes. We are currently developing more sensitive approaches (DIGE and iTRAQ
252 technologies) that will hopefully help to further explore the proteome of adipose tissue
253 components. Notwithstanding these limitations, a recent cDNA microarray analysis of whole
254 adipose tissue samples from omental and subcutaneous depots of lean to mildly obese
255 individuals revealed that genes showing greater differential expression between the two depots
256 were essentially expressed by the non-adipocyte component of adipose tissue. Although, as
257 reported by the authors, some blood contamination remained in their samples, in our study all
258 traces of blood were removed during the isolation of SVF, thus assuring that differences are to
259 be ascribed to the stromal vascular components. Together, these findings support the notion
260 that SVF contributes to major differences between VAT and SAT, at least in lean individuals,
261 which highlights the relevance of this component to maintain the distinct identity of each fat
262 depot.

263 Analysis of SVF from SAT and VAT confirmed variations in several proteins identified in a
264 recent comparative proteomic study of whole VAT and SAT from obese subjects (16). These
265 include up-regulation of ANXA5 in SAT and of hSP56, ALDH1A1, and KRT7, 8, 18 and 19 in
266 VAT, thus pointing out the usefulness of these proteins as selective markers of each fat depot
267 and, in particular, of their corresponding non-adipocyte fraction. Given that these proteins were
268 observed to vary between SAT and VAT both in lean (our study) and obese individuals (16), it
269 seems reasonable to propose that depot-specific differences in these proteins do not contribute
270 significantly to the distinct functional behavior of the two fat pads with regards to obesity and
271 related disorders.

272 The SVF of adipose tissue expresses several adipokines involved in the regulation of insulin
273 action, including omentin and visfatin (18, 19). Accordingly, our proteomic analysis confirmed
274 the presence of these two adipokines in SVF, both being more abundant in VAT than in SAT. In
275 this regard, while the selective expression of omentin in VAT SVF has been clearly established
276 (20), controversial results supporting either enrichment of visfatin mRNA in VAT (18) or
277 similar mRNA expression levels in VAT and SAT (21) have been reported. Discrepancies

278 between these reports and our study could be accounted for by the occurrence of differences
279 between visfatin transcript and protein levels. Nevertheless, it is worthy to mention that, in
280 contrast to that revealed by the analysis of the separate fractions, we observed no differences in
281 visfatin protein content when the proteomes of whole VAT and SAT were compared. Together,
282 these observations indicate that analysis of the separate fractions may be critical for the
283 identification of differentially expressed proteins between VAT and SAT. In this scenario, a key
284 finding of our study has been the identification of the nuclear envelope proteins lamin A and C
285 (lamin A/C), which we found overexpressed in SAT SVF. Mutations in the gene encoding
286 lamin A/C (LMNA) or its processing enzymes have been described linked to inherited partial
287 lipodystrophies (i.e., Dunnigan-type familial partial lipodystrophy, FPLD), which are
288 characterized by loss of subcutaneous fat and excess intraabdominal fat as well as insulin
289 resistance, type 2 diabetes, dyslipidemia and hepatic steatosis (22). Accordingly, obese and type
290 2 diabetes patients exhibit altered mRNA levels of lamin A/C in SAT (23). The higher
291 expression of lamin A/C in SAT SVF vs. VAT SVF demonstrated herein is in contrast to that
292 found in isolated adipocytes from human omental and subcutaneous fat, which show no
293 differences in protein expression of the two lamins (24). Interestingly, transgenic mice
294 expressing a mutated form of LMNA in adipose tissue, which exhibit many of the features of
295 human FPLD, show fully functional mature adipocytes whereas preadipocytes are unable to
296 differentiate into mature adipocytes (25), thus pointing out the relevance of lamin in normal
297 functioning of preadipocytes. Indeed, a role for lamin A/C in adipocyte differentiation has been
298 suggested based on its ability to associate with the adipocyte differentiation factor, sterol
299 response element binding protein 1 (SREBP1) (26). In all, these data and our findings support
300 the view that the preferential expression of lamin A/C in SAT, specifically in SVF
301 preadipocytes of this depot, may contribute to the higher susceptibility of SAT to laminopathy-
302 associated lipodystrophies when compared to VAT.

303 Besides lamin A/C, other proteins related to cellular structure and cytoskeleton were also
304 differentially expressed in SVF of VAT and SAT. Of particular interest is ezrin, a member of
305 the ERM (Ezrin/Radixin/Moesin) family which acts as membrane-cytoskeletal linker regulating

306 cortical morphogenesis and cell adhesion (27). These proteins, which are expressed in
307 endothelial cells (28), have been demonstrated to play a role in the adhesion of leukocytes to the
308 endothelium (28), and to mediate TNF- α -induced increases in both endothelial permeability
309 (29) and monocyte trans migratory activity (30). In this scenario, the observation that ezrin is
310 highly expressed in VAT SVF raises the possibility that this protein may be related to the
311 increased numbers of lymphocytes observed in visceral when compared to subcutaneous human
312 adipose tissue (31, 32) as well as to the preferential macrophage infiltration into VAT *vs.* SAT
313 observed in lean individuals and that has been shown to be exaggerated by central adiposity (32,
314 33). Given the demonstrated involvement of macrophages (34) and more recently, also of
315 lymphocytes (35), in the initiation and propagation of adipose tissue inflammation as well as in
316 the development of insulin resistance, it is conceivable that enhanced ezrin expression in VAT
317 SVF might underlie, at least in part, the increased clinical morbidity and differences in
318 metabolism in VAT relative to SAT.

319 In addition to ezrin, our study has enabled identification of other proteins whose expression
320 in adipose tissue has not been documented previously. This is the case of VAT-1, a synaptic
321 vesicle membrane protein widely expressed in the CNS and thought to be involved in nerve
322 signal transmission (36). Herein, we have shown that both VAT-1 mRNA and protein are
323 present in human adipose tissue, which demonstrates that VAT-1 is also expressed in peripheral
324 organs and, specifically, in fat SVF. Whether VAT-1 is a protein component of the autonomic
325 nervous system innervating adipose tissue remains to be determined. Nevertheless, its
326 differential expression in VAT *vs.* SAT SVF could reflect the dissimilar distribution of motor
327 afferent nerves and/or of the sensory innervation conveying information from adipose tissue to
328 the brain that has been depicted for the two fat pads (37).

329 Our study has enabled to confirm at proteomic scale previous transcriptomic data in mice on
330 the higher expression of the enzyme ALDH1A1 in VAT preadipocytes in comparison to their
331 counterparts from SAT (11). In addition, we also observed up-regulation of the isozyme
332 ALDH1A2 in VAT SVF at mRNA and protein levels. These two enzymes catalyze the
333 oxidation of the retinol metabolite, retinal, to retinoic acid (RA) (38). Together, these findings

334 support the view that VAT preadipocytes may produce higher levels of RA than SAT
335 preadipocytes. In view of the demonstrated effects of RA on adipogenesis (39), it is conceivable
336 that distinct depot-specific RA production underlies the differential capacity for differentiation
337 exhibited by visceral and subcutaneous preadipocytes (40, 41).

338 In sum, we have characterized for the first time the proteome of the two fractions that
339 compose adipose tissue, SVF and mature adipocytes, from lean individuals, thus broadening the
340 current knowledge on the protein map of human adipose tissue. Furthermore, comparison of
341 visceral and subcutaneous fat depot proteomes has allowed us to discover differentially
342 expressed proteins which could represent new adipose markers of adipose-related pathologies
343 that affect unevenly to the different fat depots, such as visceral obesity and associated metabolic
344 syndrome derived disorders or several forms of lipodistrophy that mainly affect to SAT.

345

346 **Acknowledgements**

347

348 Mass spectrometry was performed at the Proteomics Facility (SCAI) of the University of
349 Córdoba, which is Node 6 of the ProteoRed Consortium financed by Genoma España and
350 belongs to the Andalusian Platform for Genomics, Proteomics and Bioinformatics. Antibodies
351 against human lamin A/C and ezrin were kindly provided by Dr. Carlos Lopez-Otín (Univ.
352 Oviedo, Spain) and Dr. Francisco Sánchez-Madrid (Hospital Universitario de la Princesa,
353 Madrid, Spain), respectively.

354

355 **Table 1** Biometric parameters of the individuals included in the study

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

<i>n</i>	14
Age (years)	56 ± 13
Weight (Kg)	66.6 ± 16
Height (cm)	170 ± 7
BMI (Kg/m ²)	22.8 ± 2.1
Glucose (mmol/l)	6.0 ± 0.2
Total cholesterol (mmol/l)	5.36 ± 0.6
Triglycerides (mmol/l)	1.61 ± 0.3
Insulin (μU/ml)	9.67 ± 0.4

Data are means ± SD

<i>Proteins identified by MALDI-TOF/TOF significantly increased in SVF of VAT vs. SAT</i>									
Spot number	Mean fold change ^a	Protein name	Symbol	Accession number	MW (kDa)	pI	Pep. Count ^b	Total Ion Score ^b	<i>P</i> value ^c
1	4.08	Ezrin	EZR	NP_003370	69.5	5.94	20	130	0.0119
2	1.80	Transferrin	TF	AAB22049	77.0	6.85	42	503	0.0249
3	7.58	Aldehyde dehydrogenase 1 family, member A2	ALDH1A2	BAA34785	56.7	5.84	17	347	0.0251
4	1.53	Coronin, actin binding protein, 1A	CORO1A	NP_009005	51.7	6.12	13	85	0.0409
5	1.88	Nicotinamide phosphoribosyltransferase	VISFATIN	NP_005737	55.7	6.69	12	142	0.0494
6	5.79	Keratin 7 ^d	KRT7	AAH02700	51.4	5.42	25	398	0.0345
7	2.98	Aldehyde dehydrogenase 1 family, member A1	ALDH1A1	AAC51652	55.4	6.30	10	89	0.0243
8	3.35	Keratin 8 ^d	KRT8	AAH73760	53.8	5.52	34	612	0.0297
9	3.98	Phosphoglycerate dehydrogenase	PHGDH	AAD51415	57.4	6.29	12	175	0.0086
10	2.54	Aldehyde dehydrogenase 1 family, member B1	ALDH1B1	P30837	57.7	6.36	15	300	0.0211
11	3.99	Selenium binding protein 1 ^d	hSP56	NP_003935	52.9	5.93	19	189	0.0386
12	5.22	Keratin 18 ^d	KRT18	CAA31377	47.3	5.27	27	422	0.0083
13	3.44	Annexin A7	ANXA7	BAD96272	50.5	6.77	15	131	ND
14	7.13	Keratin 19 ^d	KRT19	NP_002267	44.1	5.04	32	609	0.0034
15	3.50	Intelectin 1 (Omentin)	ITLN1	AAS49907	35.5	5.66	7	261	0.0480
16	1.92	Annexin A9	ANXA9	NP_003559	38.6	5.53	18	138	0.0103
17	2.60	Annexin A3	ANXA3	NP_005130	36.5	5.63	19	708	0.0163

376 **Table 2b**
377

<i>Proteins identified by MALDI-TOF/TOF significantly increased in SVF of SAT vs. VAT</i>									
Spot number	Mean fold change ^a	Protein name	Symbol	Accession number	MW (KDa)	pI	Pep. Count ^b	Total Ion Score ^b	<i>P</i> value ^c
1	1.86	Collagen, type VI, alpha 1	COL6A1	NP_001839	109.6	5.26	17	346	0.0101
2	2.02	Lamin A/C	LMNA	NP_005563	65.2	6.40	15	97	0.0463
3	1.81	Chaperonin containing TCP1, subunit 8	TCP-1-theta	BAB43952	59.3	5.70	10	86	ND
4	1.98	Vesicle amine transport protein 1 homolog	VAT-1	NP_006364	41.7	6.17	14	209	0.0450
5	3.75	Heat shock 70kDa protein 1A	HSP70.1	BAD93055	78.0	5.97	19	281	0.0079
6	1.90	Carbonic anhydrase I	CA1	NP_001729	28.9	6.59	14	779	0.0410
7	1.60	Annexin A5 ^d	ANXA5	AAH01429	35.8	4.94	21	701	0.0341

378

379 Spot numbers correspond to those on Fig. 2.

380 ^a Mean fold change indicates the average volume ratio (Visceral vs. Subcutaneous) of
381 four independent individuals.

382 ^b Pep. count and Total Ion score values correspond to Mascot scores.

383 ^c P-value of Student's t-test; $P < 0.05$.

384 ^d Proteins also identified as differentially expressed in the same fat depot in the
385 proteome of whole adipose tissue.

386 ND, Differences in these proteins were observed only in two out of the four SVF
387 proteomes analyzed.

388

389 **Figures**

390 **Fig. 1** 2D-PAGE of whole adipose tissue (upper panels) and isolated mature adipocytes
391 (lower panels) of VAT (left panels) and SAT (right panels) from one individual.
392 Proteins were separated on a 2-DE gel using 18 cm pH 3-10 NL strips in the first
393 dimension and 12% SDS-PAGE gels in the second dimension, as described in Research
394 Design and Methods. Molecular weight standards were loaded on the second dimension
395 (right). Differentially expressed proteins between the two adipose tissue depots are
396 indicated with arrows. The numbers correspond to the spot numbers in supplemental
397 Table 1.

398 **Fig. 2** Characterization of the proteome of VAT and SAT SVF. A) Representative 2D-
399 PAGE of paired samples of VAT (left panel) and SAT (right panel) SVF from one
400 individual. Proteins with significant up-regulation in each fat depot are indicated by
401 arrows. The numbers correspond to the spot numbers in Table 2. B) Magnification of
402 the boxed region of the 2D-PAGE gels showing 5 proteins with higher expression in
403 either VAT SVF (PHGDH, Ezrin and ANXA3) or SAT SVF (Lamin A/C and VAT-1)
404 from two different individuals (Ind1 and 2).

405 **Fig. 3** A) Representative image of the proteome region that contains KRT18, HSP70
406 and ANXA5 (MW: 35-45 kDa and pI: 4.9-5.4) in whole adipose tissue, SVF and mature
407 adipocytes of VAT and SAT. B) Quantification of their relative abundance in whole
408 adipose tissue (n=3), SVF (n=4) and mature adipocytes (n=3) of both fat depots. * $P <$
409 0.05. V- (Visceral), S- (subcutaneous).

410 **Fig. 4** Protein abundance (by Western blot) of Lamin A/C (A) and Ezrin (B) in SVF
411 from VAT and SAT. The results were normalized for β -actin density. * $P <$ 0.05,
412 (\pm S.E.M.). SVF from 4 individuals were used for these studies. Insets show
413 representative Western blots.

414 **Fig. 5** Mean (\pm S.E.M.) mRNA levels of VAT-1 (A; n=6) and ALDH1A2 (B; n=4) in
415 SVF of VAT and SAT. Results are expressed in arbitrary units. * $P <$ 0.05.

416 **References**

417

418

419

420 1. **Kershaw EE, Flier JS** 2004 Adipose tissue as an endocrine organ. *J Clin*

421 *Endocrinol Metab* 89:2548-2556

422 2. **Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW** 2003

423 Integrative physiology of human adipose tissue. *Int J Obes Relat Metab Disord*

424 27:875-888

425 3. **Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW** 2004 Comparison

426 of the release of adipokines by adipose tissue, adipose tissue matrix, and

427 adipocytes from visceral and subcutaneous abdominal adipose tissues of obese

428 humans. *Endocrinology* 145:2273-2282

429 4. **Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger**

430 **GJ, Stulnig TM** 2007 Human adipose tissue macrophages are of an anti-

431 inflammatory phenotype but capable of excessive pro-inflammatory mediator

432 production. *Int J Obes (Lond)* 31:1420-1428

433 5. **Shoelson SE, Lee J, Goldfine AB** 2006 Inflammation and insulin resistance. *J*

434 *Clin Invest* 116:1793-1801

435 6. **Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF** 2002 Depot-

436 specific hormonal characteristics of subcutaneous and visceral adipose tissue

437 and their relation to the metabolic syndrome. *Horm Metab Res* 34:616-621

438 7. **Hamdy O, Porramatikul S, Al-Ozairi E** 2006 Metabolic obesity: the paradox

439 between visceral and subcutaneous fat. *Curr Diabetes Rev* 2:367-373

440 8. **Araujo-Vilar D, Lattanzi G, Gonzalez-Mendez B, Costa-Freitas AT, Prieto**

441 **D, Columbaro M, Mattioli E, Victoria B, Martinez-Sanchez N, Ramazanov**

442 **A, Fraga M, Beiras A, Forteza J, Dominguez-Gerpe L, Calvo C, Lado-**

443 **Abeal J** 2009 Site-dependent differences in both prelamins A and adipogenic

444 genes in subcutaneous adipose tissue of patients with type 2 familial partial

445 lipodystrophy. *J Med Genet* 46:40-48

446 9. **Mastro R, Hall M** 1999 Protein delipidation and precipitation by tri-n-

447 butylphosphate, acetone, and methanol treatment for isoelectric focusing and

448 two-dimensional gel electrophoresis. *Anal Biochem* 273:313-315

449 10. **Chen X, Hess S** 2008 Adipose proteome analysis: focus on mediators of insulin

450 resistance. *Expert Rev Proteomics* 5:827-839

451 11. **Gesta S, Bluher M, Yamamoto Y, Norris AW, Berndt J, Kralisch S,**

452 **Boucher J, Lewis C, Kahn CR** 2006 Evidence for a role of developmental

453 genes in the origin of obesity and body fat distribution. *Proc Natl Acad Sci U S*

454 *A* 103:6676-6681

455 12. **Niesler CU, Siddle K, Prins JB** 1998 Human preadipocytes display a depot-

456 specific susceptibility to apoptosis. *Diabetes* 47:1365-1368

457 13. **Van Harmelen V, Rohrig K, Hauner H** 2004 Comparison of proliferation and

458 differentiation capacity of human adipocyte precursor cells from the omental and

459 subcutaneous adipose tissue depot of obese subjects. *Metabolism* 53:632-637

460 14. **Boden G, Duan X, Homko C, Molina EJ, Song W, Perez O, Cheung P,**

461 **Merali S** 2008 Increase in endoplasmic reticulum stress-related proteins and

462 genes in adipose tissue of obese, insulin-resistant individuals. *Diabetes* 57:2438-

463 2444

- 464 15. **Ahmed M, Neville MJ, Edelmann MJ, Kessler BM, Karpe F** 2009 Proteomic
465 Analysis of Human Adipose Tissue After Rosiglitazone Treatment Shows
466 Coordinated Changes to Promote Glucose Uptake. *Obesity (Silver Spring)*
- 467 16. **Perez-Perez R, Ortega-Delgado FJ, Garcia-Santos E, Lopez JA, Camafeita
468 E, Ricart W, Fernandez-Real JM, Peral B** 2009 Differential Proteomics of
469 Omental and Subcutaneous Adipose Tissue Reflects Their Unalike Biochemical
470 and Metabolic Properties. *J Proteome Res* 8:1682-93
- 471 17. **van Beek EA, Bakker AH, Kruyt PM, Hofker MH, Saris WH, Keijzer J** 2007
472 Intra- and interindividual variation in gene expression in human adipose tissue.
473 *Pflugers Arch* 453:851-861
- 474 18. **Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto
475 K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E,
476 Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M,
477 Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I** 2005
478 Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.
479 *Science* 307:426-430
- 480 19. **Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H,
481 Randeve HS** 2008 Omentin-1, a novel adipokine, is decreased in overweight
482 insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo
483 regulation of omentin-1 by insulin and glucose. *Diabetes* 57:801-8.
- 484 20. **Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C**
485 2005 Genomic structure of human omentin, a new adipocytokine expressed in
486 omental adipose tissue. *Biochim Biophys Acta* 1732:96-102
- 487 21. **Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR,
488 Stumvoll M, Bluher M** 2005 Plasma visfatin concentrations and fat depot-
489 specific mRNA expression in humans. *Diabetes* 54:2911-2916
- 490 22. **Garg A, Agarwal AK** 2009 Lipodystrophies: Disorders of adipose tissue
491 biology. *Biochim Biophys Acta* 1791:507-513
- 492 23. **Miranda M, Chacon MR, Gutierrez C, Vilarrasa N, Gomez JM, Caubet E,
493 Megia A, Vendrell J** 2008 LMNA mRNA expression is altered in human
494 obesity and type 2 diabetes. *Obesity (Silver Spring)* 16:1742-1748
- 495 24. **Lelliott CJ, Logie L, Sewter CP, Berger D, Jani P, Blows F, O'Rahilly S,
496 Vidal-Puig A** 2002 Lamin expression in human adipose cells in relation to
497 anatomical site and differentiation state. *J Clin Endocrinol Metab* 87:728-734
- 498 25. **Wojtanik KM, Edgemon K, Viswanadha S, Lindsey B, Haluzik M, Chen W,
499 Poy G, Reitman M, Londos C** 2009 The role of LMNA in adipose: a novel
500 mouse model of lipodystrophy based on the Dunnigan-type familial partial
501 lipodystrophy mutation. *J Lipid Res* 50:1068-1079
- 502 26. **Lloyd DJ, Trembath RC, Shackleton S** 2002 A novel interaction between
503 lamin A and SREBP1: implications for partial lipodystrophy and other
504 laminopathies. *Hum Mol Genet* 11:769-777
- 505 27. **Louvet-Vallee S** 2000 ERM proteins: from cellular architecture to cell
506 signaling. *Biol Cell* 92:305-316
- 507 28. **Barreiro O, Yanez-Mo M, Serrador JM, Montoya MC, Vicente-
508 Manzanares M, Tejedor R, Furthmayr H, Sanchez-Madrid F** 2002 Dynamic
509 interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel
510 endothelial docking structure for adherent leukocytes. *J Cell Biol* 157:1233-
511 1245
- 512 29. **Koss M, Pfeiffer GR, 2nd, Wang Y, Thomas ST, Yerukhimovich M, Gaarde
513 WA, Doerschuk CM, Wang Q** 2006 Ezrin/radixin/moesin proteins are

- 514 phosphorylated by TNF-alpha and modulate permeability increases in human
515 pulmonary microvascular endothelial cells. *J Immunol* 176:1218-1227
- 516 30. **Lim S, Ryu J, Shin JA, Shin MJ, Ahn YK, Kim JJ, Han KH** 2009 Tumor
517 Necrosis Factor- α Potentiates RhoA-Mediated Monocyte Transmigratory
518 Activity In Vivo at a Picomolar Level. *Arterioscler Thromb Vasc Biol*
- 519 31. **Duffaut C, Zakaroff-Girard A, Bourlier V, Decaunes P, Maumus M,**
520 **Chiotasso P, Sengenès C, Lafontan M, Galitzky J, Bouloumie A** 2009
521 Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as
522 an adipochemokine and T lymphocytes as lipogenic modulators. *Arterioscler*
523 *Thromb Vasc Biol* 29:1608-1614
- 524 32. **O'Rourke RW, Metcalf MD, White AE, Madala A, Winters BR, Maizlin, II,**
525 **Jobe BA, Roberts CT, Jr., Slifka MK, Marks DL** 2009 Depot-specific
526 differences in inflammatory mediators and a role for NK cells and IFN-gamma
527 in inflammation in human adipose tissue. *Int J Obes (Lond)*
- 528 33. **Harman-Boehm I, Bluher M, Redel H, Sion-Vardy N, Ovadia S, Avinoach**
529 **E, Shai I, Kloting N, Stumvoll M, Bashan N, Rudich A** 2007 Macrophage
530 infiltration into omental versus subcutaneous fat across different populations:
531 effect of regional adiposity and the comorbidities of obesity. *J Clin Endocrinol*
532 *Metab* 92:2240-2247
- 533 34. **Hotamisligil GS** 2006 Inflammation and metabolic disorders. *Nature* 444:860-
534 867
- 535 35. **Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu**
536 **M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R** 2009
537 CD8+ effector T cells contribute to macrophage recruitment and adipose tissue
538 inflammation in obesity. *Nat Med* 15:914-920
- 539 36. **Linial M, Miller K, Scheller RH** 1989 VAT-1: an abundant membrane protein
540 from Torpedo cholinergic synaptic vesicles. *Neuron* 2:1265-1273
- 541 37. **Kreier F, Kap YS, Mettenleiter TC, van Heijningen C, van der Vliet J,**
542 **Kalsbeek A, Sauerwein HP, Fliers E, Romijn JA, Buijs RM** 2006 Tracing
543 from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of
544 the brain in type 2 diabetes. *Endocrinology* 147:1140-1147
- 545 38. **Marchitti SA, Brocker C, Stagos D, Vasiliou V** 2008 Non-P450 aldehyde
546 oxidizing enzymes: the aldehyde dehydrogenase superfamily. *Expert Opin Drug*
547 *Metab Toxicol* 4:697-720
- 548 39. **Bonet ML, Ribot J, Felipe F, Palou A** 2003 Vitamin A and the regulation of
549 fat reserves. *Cell Mol Life Sci* 60:1311-1321
- 550 40. **Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby**
551 **JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S** 1997 Activators of
552 peroxisome proliferator-activated receptor gamma have depot-specific effects on
553 human preadipocyte differentiation. *J Clin Invest* 100:3149-3153
- 554 41. **Tchkonina T, Giorgadze N, Pirtskhalava T, Thomou T, DePonte M, Koo A,**
555 **Forse RA, Chinnappan D, Martin-Ruiz C, von Zglinicki T, Kirkland JL**
556 2006 Fat depot-specific characteristics are retained in strains derived from single
557 human preadipocytes. *Diabetes* 55:2571-2578
- 558

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

